All‐DNA nanomedicines have emerged as potential anti‐tumor drugs. DNA nanotechnology provides all‐DNA nanomedicines with unlimited possibilities in controlling the diversification of size, shape, and loads of the therapeutic motifs. As DNA is a biological polymer, it is possible to genetically encode and produce the all‐DNA nanomedicines in living bacteria. Herein, DNA‐dendrimer‐based nanomedicines are designed to adapt to the biological production, which is constructed by the flexible 3‐arm building blocks to enable a highly efficient one‐pot DNA assembly. For the first time, a DNA nanomedicine, D4‐3‐As‐DzSur, is successfully genetically encoded, biotechnologically produced, and directly self‐assembled. The performance of the biologically produced D4‐3‐As‐DzSur in targeted gene regulation has been confirmed by in vitro and in vivo studies. The biological production capability will fulfill the low‐cost and large‐scale production of all‐DNA nanomedicines and promote clinical applications.

中文翻译：

---

基于一键装配DNA树状大分子的靶向基因调控的遗传编码和生物生产的全DNA纳米药物。

全DNA纳米药物已成为潜在的抗肿瘤药物。DNA纳米技术为全DNA纳米药物提供了无限的可能性来控制治疗基序的大小，形状和负荷的多样化。由于DNA是生物聚合物，因此可以在活细菌中进行基因编码并生产全DNA纳米药物。在此，基于DNA树状大分子的纳米药物旨在适应生物生产，该产品由灵活的3臂构件构建，可实现高效的一锅式DNA组装。DNA纳米药物D4-3-As‐DzSur首次成功地进行了基因编码，生物技术生产并直接自组装。体外和体内研究证实了生物生产的D4-3-As-DzSur在靶向基因调控中的性能。